RNAi drugmaker City prices $200 million IPO

· Health · United States

City, a next-generation RNAi drugmaker, priced a $200 million initial public offering, according to BioPharma Dive. The offering will support a trio of medicines that are in or nearing clinical testing, as well as earlier research into RNAi treatments designed to reach tissues outside the liver. RNAi is a technique that silences disease-causing genes; most existing programs concentrate on liver targets, so extending delivery to other tissues is a major research frontier. The listing adds to a recent pickup in biotech IPO activity. Proceeds are earmarked for advancing the company's clinical-stage pipeline and early-stage tissue-targeting work.

Why it matters：The IPO shows investor appetite returning for clinical-stage RNAi companies and could accelerate efforts to move gene-silencing drugs beyond the liver, where most current competition sits.

Key points

  • The $200 million offering supports three medicines in or nearing clinical testing.
  • Funding also covers early RNAi research into tissues outside the liver.
  • City is described as a next-generation RNAi drugmaker.

Sources (original reporting)

More stories from this day